ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have received an average recommendation of “Moderate Buy” from the six research firms that are covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $8.50.

ALXO has been the topic of a number of recent research reports. Jefferies Financial Group cut ALX Oncology from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $12.00 to $2.00 in a report on Thursday, December 19th. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of ALX Oncology in a report on Wednesday, December 18th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a report on Wednesday, December 18th.

ALX Oncology Stock Performance

Shares of ALXO opened at $1.65 on Friday. The stock’s 50-day simple moving average is $1.59 and its 200 day simple moving average is $2.46. The stock has a market capitalization of $87.02 million, a price-to-earnings ratio of -0.55 and a beta of 0.98. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. ALX Oncology has a 52-week low of $1.19 and a 52-week high of $17.83.

Insider Buying and Selling at ALX Oncology

In other news, Director Rekha Hemrajani acquired 30,000 shares of ALX Oncology stock in a transaction dated Monday, December 2nd. The shares were purchased at an average cost of $1.55 per share, for a total transaction of $46,500.00. Following the transaction, the director now owns 33,000 shares of the company’s stock, valued at $51,150. This trade represents a 1,000.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders have sold a total of 14,443 shares of company stock valued at $23,309 in the last 90 days. Corporate insiders own 33.40% of the company’s stock.

Hedge Funds Weigh In On ALX Oncology

Institutional investors have recently modified their holdings of the company. Hsbc Holdings PLC bought a new position in shares of ALX Oncology during the 2nd quarter valued at about $63,000. AQR Capital Management LLC increased its position in shares of ALX Oncology by 50.7% during the 2nd quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock valued at $109,000 after purchasing an additional 6,080 shares during the last quarter. SG Americas Securities LLC increased its position in shares of ALX Oncology by 33.6% during the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after purchasing an additional 6,888 shares during the last quarter. Algert Global LLC bought a new position in shares of ALX Oncology during the 2nd quarter valued at about $249,000. Finally, GSA Capital Partners LLP bought a new position in shares of ALX Oncology during the 3rd quarter valued at about $88,000. 97.97% of the stock is currently owned by institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.